Centre de diagnostic et de thérapeutique, Hôpital Hôtel-Dieu, AP-HP, Université Paris Cité, Place du Parvis Notre-Dame, 75004 Paris, France.
Surveillance des maladies cardio-neuro-vasculaires, Direction des maladies non transmissibles, Santé publique France, Saint-Maurice, France.
Eur J Prev Cardiol. 2024 Nov 18;31(16):1939-1947. doi: 10.1093/eurjpc/zwae194.
To evaluate the impact of cardiac rehabilitation (CR) on optimization of secondary prevention treatments for acute coronary syndrome (ACS), medication persistence, medical follow-up, rehospitalization, and all-cause mortality.
The National Health Insurance database was used to identify all patients hospitalized for ACS in France in 2019 and those among them who received CR. Patients' characteristics and outcomes were described and compared between CR and non-CR patients. Poisson regression models were used to identify the impact of CR after adjusting for confounders. A Cox model was fitted to identify the variables related to mortality after adjustment for medication persistence and cardiologic follow-up. In 2019, 22% of 134 846 patients hospitalized for ACS in France received CR within 6 months of their discharge. After 1 year, only 60% of patients who did not receive CR were still taking BASI (combination of beta-blockers, antiplatelet agents, statins, and renin-angiotensin-aldosterone system inhibitors) drugs. This rate and the medical follow-up rate were higher in patients who received CR. Two years after the ACS event, patients who received CR had better medical follow-up and lower mortality risk, after adjusting for cofounding variables [adjusted hazard ratio all-cause mortality = 0.65 (0.61-0.69)]. After adjustment for the dispensing of cardiovascular drugs and cardiologic follow-up, the independent effect of CR was not as strong but remained significant [hazard ratio = 0.90 (95% confidence interval: 0.84-0.95)].
Patients who received CR after hospitalization for ACS had a better prognosis. Optimization of efficient secondary prevention strategies, improved medication persistence, and enhanced cardiologic follow-up seemed to play a major role.
评估心脏康复(CR)对优化急性冠状动脉综合征(ACS)二级预防治疗、药物维持、医学随访、再住院和全因死亡率的影响。
利用国家健康保险数据库,确定了 2019 年法国因 ACS 住院的所有患者,以及其中接受 CR 的患者。描述了 CR 患者和非 CR 患者的特征和结局,并进行了比较。采用泊松回归模型在调整混杂因素后,确定了 CR 的影响。采用 Cox 模型在调整药物维持和心脏随访后,确定与死亡率相关的变量。2019 年,法国因 ACS 住院的 134846 例患者中,有 22%在出院后 6 个月内接受了 CR。1 年后,未接受 CR 的患者中,仍有 60%在服用 BASI(β受体阻滞剂、抗血小板药物、他汀类药物和肾素-血管紧张素-醛固酮系统抑制剂的组合)药物。在接受 CR 的患者中,该比率和医学随访率更高。ACS 事件发生两年后,在调整混杂变量后,接受 CR 的患者具有更好的医学随访和更低的死亡风险[全因死亡率调整后的危害比=0.65(0.61-0.69)]。在调整心血管药物的配药和心脏随访后,CR 的独立作用虽然减弱,但仍然显著[风险比=0.90(95%置信区间:0.84-0.95)]。
ACS 住院后接受 CR 的患者预后更好。优化有效的二级预防策略、提高药物维持率和增强心脏随访似乎发挥了重要作用。